JP2023529196A - 急性心房細動の治療のためのサルカルディン投与 - Google Patents

急性心房細動の治療のためのサルカルディン投与 Download PDF

Info

Publication number
JP2023529196A
JP2023529196A JP2022575898A JP2022575898A JP2023529196A JP 2023529196 A JP2023529196 A JP 2023529196A JP 2022575898 A JP2022575898 A JP 2022575898A JP 2022575898 A JP2022575898 A JP 2022575898A JP 2023529196 A JP2023529196 A JP 2023529196A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
tmax
dose
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022575898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529196A5 (cg-RX-API-DMAC10.html
Inventor
エリオット，ゲイリー
ギリングス，ミレイユ
グデノフ，ロバート
メイソン，ジェイ
ラジシェフスキ，ヴァルデマール
ロマーノ，スザンヌ
Original Assignee
フヤバイオ インターナショナル，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フヤバイオ インターナショナル，エルエルシー filed Critical フヤバイオ インターナショナル，エルエルシー
Publication of JP2023529196A publication Critical patent/JP2023529196A/ja
Publication of JP2023529196A5 publication Critical patent/JP2023529196A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022575898A 2020-06-12 2021-06-11 急性心房細動の治療のためのサルカルディン投与 Pending JP2023529196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038664P 2020-06-12 2020-06-12
US63/038,664 2020-06-12
PCT/US2021/037098 WO2021252959A1 (en) 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation

Publications (2)

Publication Number Publication Date
JP2023529196A true JP2023529196A (ja) 2023-07-07
JP2023529196A5 JP2023529196A5 (cg-RX-API-DMAC10.html) 2024-06-18

Family

ID=78824214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575898A Pending JP2023529196A (ja) 2020-06-12 2021-06-11 急性心房細動の治療のためのサルカルディン投与

Country Status (14)

Country Link
US (2) US11813245B2 (cg-RX-API-DMAC10.html)
EP (1) EP4164633A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023529196A (cg-RX-API-DMAC10.html)
KR (1) KR20230024347A (cg-RX-API-DMAC10.html)
CN (1) CN116723836A (cg-RX-API-DMAC10.html)
AU (1) AU2021288056A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022025216A2 (cg-RX-API-DMAC10.html)
CA (1) CA3182015A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022003501A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023000194A2 (cg-RX-API-DMAC10.html)
IL (1) IL298907A (cg-RX-API-DMAC10.html)
MX (1) MX2022015834A (cg-RX-API-DMAC10.html)
PH (1) PH12022553396A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021252959A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
WO2026036095A1 (en) * 2024-08-08 2026-02-12 Huyabio International, Llc J-Tp PROTECTION

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511473A (ja) * 2009-11-17 2013-04-04 フヤ バイオサイエンス インターナショナル エルエルシー 心房細動の治療
JP2022514537A (ja) * 2018-12-13 2022-02-14 フヤ バイオサイエンス インターナショナル エルエルシー 急性心房細動の処置のためのサルカルディン投与
JP2022518906A (ja) * 2019-01-29 2022-03-17 フヤ バイオサイエンス インターナショナル エルエルシー サルカルディン塩

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
WO2011062903A2 (en) * 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511473A (ja) * 2009-11-17 2013-04-04 フヤ バイオサイエンス インターナショナル エルエルシー 心房細動の治療
JP2022514537A (ja) * 2018-12-13 2022-02-14 フヤ バイオサイエンス インターナショナル エルエルシー 急性心房細動の処置のためのサルカルディン投与
JP2022518906A (ja) * 2019-01-29 2022-03-17 フヤ バイオサイエンス インターナショナル エルエルシー サルカルディン塩

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, vol. 140(Suppl_1), JPN6025025794, November 2019 (2019-11-01), pages 11495, ISSN: 0005752536 *
PHARMACOLOGY AND THERAPEUTICS, vol. 18(5), JPN6025025797, 2013, pages 453 - 459, ISSN: 0005752537 *
日臨麻会誌, vol. 32(4), JPN6025025799, 2012, pages 590 - 596, ISSN: 0005752538 *

Also Published As

Publication number Publication date
US11813245B2 (en) 2023-11-14
US20240058304A1 (en) 2024-02-22
PH12022553396A1 (en) 2024-04-22
IL298907A (en) 2023-02-01
EP4164633A4 (en) 2024-07-31
WO2021252959A1 (en) 2021-12-16
CL2022003501A1 (es) 2023-06-09
KR20230024347A (ko) 2023-02-20
BR112022025216A2 (pt) 2023-04-04
EP4164633A1 (en) 2023-04-19
US12465587B2 (en) 2025-11-11
CN116723836A (zh) 2023-09-08
US20210386708A1 (en) 2021-12-16
AU2021288056A1 (en) 2023-02-09
CO2023000194A2 (es) 2023-03-27
CA3182015A1 (en) 2021-12-16
MX2022015834A (es) 2023-04-04

Similar Documents

Publication Publication Date Title
AU2019397511B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
CN102056603A (zh) 决奈达隆用于预防持续性心房纤颤
US12465587B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
JP6116908B2 (ja) 心房細動の治療
JP2013511473A5 (cg-RX-API-DMAC10.html)
CZ20011807A3 (cs) Způsob výroby farmaceutického prostředku, farmaceutický prostředek a jeho použití
JP2013511472A5 (cg-RX-API-DMAC10.html)
EP2133075A1 (en) Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion
EA045624B1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
US20260041665A1 (en) J-Tp Protection
EP2386300A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter
WO2019131308A1 (ja) ９‐β‐Ｄ‐アラビノフラノシルヒポキサンチンによる不整脈治療
WO2020035541A1 (en) Task-1 inhibitors for treatment of atrial arrhythmias
HK1155668A (en) Dronedarone for the prevention of permanent atrial fibrillation
HK1155667A (en) Dronedarone for the prevention of cardioversion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251215